Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Staphylococcus Aureus Vaccine in Healthy Adults
NCT02804711Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Sep 2016
- Primary completion
- Jul 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant five-antigen Staphylococcus aureus vaccine in Staphylococcus aureus infection (7 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Occurrence of injection site adverse reactions after vaccination at 21 days and Occurrence of systematic adverse reactions after vaccination at 21 days. Started Sep 2016; status: completed.
02
Drugs
recombinant five-antigen Staphylococcus aureus vaccine
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT02804711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804711.